Patients Paying More for Specialty Drugs as Costs Continue to Rise

Patients Paying More for Specialty Drugs as Costs Continue to Rise

Drug costs are rising in the United States for many patients who are undergoing costly treatments for serious diseases such as cancer and hepatitis C, according to a report from the IMS Institute for Healthcare Informatics. 

In 2013, the out-of-pocket costs for prescription drugs were fairly lopsided. That is, patients paid on average less than $5 in out-of-pocket costs for prescription drugs because of cheaper generic versions on the market. But patients needing more-expensive drugs got hit much harder, with barely 2 percent of all prescriptions accounting for 30 percent of all out-of-pocket costs. Pew’s specialty drugs project works to identify policy options that could help manage such costs.  

The report traces the discrepancy in costs to pharmaceutical companies that lose sales when generics that compete with their brand-names drugs are introduced to the market. To make up for lost revenue, the companies focus on developing treatments for more complex “orphan diseases,” which affect fewer than 200,000 people nationwide.

“The new drugs coming to market are more specialized, and more tailored to smaller populations of patients, which tends to make them more expensive because fewer people are ultimately going to take them,” Caroline F. Pearson, vice president of Avalere Health, a health care consulting firm, told The New York Times. To compensate for this trend, health plans are increasingly shifting costs to the consumer. 

The IMS report found that specialty drug costs helped push overall spending on prescription medicine in the United States to more than $329 billion in 2013, an increase of 3.2 percent. Pharmacy benefit managers—those who administer prescription drug plans—across the country predict that these costs will continue to rise, particularly among specialty drugs. CVS Caremark, for example, reported that spending on these drugs grew by 15.6 percent in 2013, compared with a rise of only 0.8 percent for traditional pharmaceuticals over the same period.  And The New York Times reported that Express Scripts projected a 63 percent increase in specialty drug spending in the United States between 2014 and 2016.

Read the report.

Spotlight on Mental Health

Composite image of modern city network communication concept

Learn the Basics of Broadband from Our Limited Series

Sign up for our four-week email course on Broadband Basics

Quick View

How does broadband internet reach our homes, phones, and tablets? What kind of infrastructure connects us all together? What are the major barriers to broadband access for American communities?

Pills illustration
Pills illustration

What Is Antibiotic Resistance—and How Can We Fight It?

Sign up for our four-week email series The Race Against Resistance.

Quick View

Antibiotic-resistant bacteria, also known as “superbugs,” are a major threat to modern medicine. But how does resistance work, and what can we do to slow the spread? Read personal stories, expert accounts, and more for the answers to those questions in our four-week email series: Slowing Superbugs.

Explore Pew’s new and improved
Fiscal 50 interactive

Your state's stats are more accessible than ever with our new and improved Fiscal 50 interactive:

  • Maps, trends, and customizable charts
  • 50-state rankings
  • Analysis of what it all means
  • Shareable graphics and downloadable data
  • Proven fiscal policy strategies

Explore

Welcome to the new Fiscal 50

Key changes include:

  • State pages that help you keep track of trends in your home state and provide national and regional context.
  • Interactive indicator pages with highly customizable and shareable data visualizations.
  • A Budget Threads feature that offers Pew’s read on the latest state fiscal news.

Learn more about the new and improved Fiscal 50.